Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(11%)
Results Posted
25%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph early_phase_1
2
22%
Ph not_applicable
3
33%
Ph phase_1
2
22%
Ph phase_2
1
11%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
2(25.0%)
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
1(12.5%)
N/ANon-phased studies
3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(4)
Terminated(3)

Detailed Status

Completed4
Withdrawn2
Terminated1
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (25.0%)
Phase 12 (25.0%)
Phase 21 (12.5%)
N/A3 (37.5%)

Trials by Status

withdrawn222%
terminated111%
active_not_recruiting111%
not_yet_recruiting111%
completed444%

Recent Activity

1 active trials
Showing 5 of 9
active_not_recruiting

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT00935090
not_yet_recruitingearly_phase_1

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

NCT07609225
completedphase_2

Image-Guided Gynecologic Brachytherapy

NCT01399658
completedphase_1

Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

NCT01480050
completedearly_phase_1

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

NCT00757549
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00935090

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Active Not Recruiting
NCT07609225Early Phase 1

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

Not Yet Recruiting
NCT01399658Phase 2

Image-Guided Gynecologic Brachytherapy

Completed
NCT01480050Phase 1

Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

Completed
NCT00757549Early Phase 1

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

Completed
NCT01283178Phase 1

Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC

Terminated
NCT02241668Not Applicable

Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma

Withdrawn
NCT01018251Not Applicable

Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer

Withdrawn
NCT00534274Not Applicable

Positron Emission Tomography Using 3'-Deoxy-3'-(18F) Fluorothymidine in Treating Women With Locally Advanced Cancer in One Breast Who Are Receiving Chemotherapy

Completed

All 9 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
9